Sign in        CH  

Login

UserName:

PassWord:

GUIDE

2005 BCSH Postion Statement on the Use of Bortezomib in Multiple Myeloma
Release date 2005/04/05
Source Confidential draft documen
Author BCSH,British Committee for Standards in Haematology
Download 2005 BCSH POSITION STATEMENT ON THE USE OF BORTEZOMIB IN MULTIPLE MYELOMA.pdf
Introduction Bortezomib (Velcade™) is a boron containing molecule which reversibly inhibits the proteasome, an intracellular organelle which is central to the breakdown of ubiquinated proteins and consequently for normal cellular homeostasis. Phase II clinical trials demonstrate it is effective for the treatment of relapsed refractory myeloma, and a phase III trial comparing bortezomib to dexamethasone showed superiority in progression free and overall survival
Originate http://guide.medlive.cn/